RedHill Biopharma (RDHL) Tops Q4 EPS Views

RedHill Biopharma (NASDAQ: RDHL) reported Q4 EPS of $0.06, $0.66 better than the analyst estimate of ($0.60).

EPS in Q413 was 0.05.

For earnings history and earnings-related data on RedHill Biopharma (RDHL) click here.

You May Also Be Interested In

• Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
• Hertz Investor Alert: Schall, Brown & Schwartz LLP Files Class Action Lawsuit Against Hertz Global Holdings, Inc. and Announces Opportunity for Investors to Lead Class Action Lawsuit
• Ameriprise Financial Launches New Advertising Campaign Showcasing the Power of Advice and a National Brand